Login to Access Video or Poster Abstract: MP09-13
Sources of Funding: None

Introduction

This study aimed to analyze the efficacy and safety of full dose antimuscarinic treatment on male patients with overactive bladder (OAB) symptoms who showed unsatisfactory improvements after low dose antimuscarinic treatments.

Methods

We retrospectively reviewed the data of 567male patients aged 40 or older with OAB symptoms between January 2013 and June 2015. All patients were treated with low dose antimuscarinics at least for 4 weeks and showed unsatisfactory symptom improvements and therefore changed to full dose antimuscarinics using 10 mg of solifenacin for more than 12 weeks. International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS) at baseline (V0), 4 weeks (V1), and 12 weeks (V2) were analyzed. Safety of treatment was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Results

Among the total patients, one showed acute urinary retention and was excluded, leaving 566 patients in the analysis. Median age, body mass index, and prostate-specific antigen were 69.0 years, 24.2 kg/m2, and 1.24 ng/dL respectively. Mean value of total IPSS and OABSS scores significantly decreased from V0 to V2 (16.73 to 13.69, and 7.33 to 5.34, respectively, all p < 0.001). All scores of each questionnaires demonstrated significant decrease except for IPSS questionnaires number 3 and 6. Four and nine patients complained constipation and thirst respectively, and all adverse effects were graded 2 or below.

Conclusions

Full dose antimuscarinic therapy using solilfenacin 5mg may be safe and effective treatment for those patients who have OAB symptoms refractory to low dose antimuscarinic therapy.

Funding

None